Arbor Investment Advisors LLC Invests $200,000 in Fresenius Medical Care AG (NYSE:FMS)

Arbor Investment Advisors LLC bought a new position in shares of Fresenius Medical Care AG (NYSE:FMS) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 8,850 shares of the company’s stock, valued at approximately $200,000.

Several other institutional investors and hedge funds have also made changes to their positions in FMS. ABC Arbitrage SA bought a new stake in shares of Fresenius Medical Care during the fourth quarter worth $4,215,000. Moran Wealth Management LLC lifted its position in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after purchasing an additional 74,621 shares during the last quarter. Quantinno Capital Management LP raised its holdings in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Fresenius Medical Care in the fourth quarter valued at about $983,000. Finally, Crossmark Global Holdings Inc. raised its holdings in shares of Fresenius Medical Care by 60.4% in the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after acquiring an additional 23,692 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Truist Financial lifted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Berenberg Bank assumed coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

Shares of Fresenius Medical Care stock opened at $23.09 on Friday. The company has a market capitalization of $13.55 billion, a PE ratio of 19.08, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a 50-day simple moving average of $23.41 and a two-hundred day simple moving average of $21.68. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.